The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer cells.
Nandini Dey
No relevant relationships to disclose
Yuliang Sun
No relevant relationships to disclose
Jennifer Carlson
No relevant relationships to disclose
Lori Friedman
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Pradip De
No relevant relationships to disclose
Brian Leyland-Jones
No relevant relationships to disclose